Pulmatrix GAAP EPS of -$0.34
Pulmatrix reported a GAAP EPS of -$0.34 for Q3 2026. The company released this financial update in a press statement.
Pulmatrix, Inc.
Pulmatrix is a biopharmaceutical company that develops inhaled therapeutic products for migraine and respiratory diseases using its proprietary iSPERSE dry powder delivery technology. The platform is designed to deliver small and large molecule drugs to the lungs for local or systemic use. Its clinical candidates include PUR3100 for acute migraine, PUR1800 for acute exacerbations of chronic obstructive pulmonary disease, and PUR1900 for allergic bronchopulmonary aspergillosis and other fungal lung infections. Development of these candidates is on hold as Pulmatrix explores opportunities to monetize the assets and its iSPERSE technology. Pulmatrix seeks to generate value through partnerships, licensing agreements, or other arrangements involving its technology and product candidates. The company is headquartered in Framingham, Massachusetts.
No SEC Form 4 filings for $PULM in the last 30 days.
See all $PULM insider activity →Pulmatrix reported a GAAP EPS of -$0.34 for Q3 2026. The company released this financial update in a press statement.
Pulmatrix (PULM) reported Q3 2026 results, highlighting progress on its merger with Eos SENOLYTIX, expected to close by year-end. The company raised $1M in a private placement related to the merger. Pulmatrix also updated investors on its clinical assets, including PUR1900, PUR3100, and PUR1800, and reported increased expenses due to merger activities. As of Q3 2026, Pulmatrix had $1.4M in cash and cash equivalents.
Eos SENOLYTIX reported interim data from a rat study of its aging drug candidate PTC-2105, showing improved motor performance and reduced fat mass. The 32-week study involves 268 rats, with the oldest cohort showing positive results. Eos plans FDA submission and human trials in 2027. The company is merging with Pulmatrix Inc. (PULM), expected to close in Q4 2026.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning PULM (Pulmatrix, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 1 bearish.
Recent PULM coverage spans earnings, mergers & acquisitions and financial news.
Negative GAAP EPS print likely reinforces cash-burn concerns and keeps valuation pressure on the stock until guidance or operating metrics improve.
Near-term focus shifts to merger closing mechanics (Nasdaq listing approval, reverse split completion, closing conditions), with cash runway tied to the deal timeline.
Merger approval may create valuation upside for Pulmatrix as it gains a novel aging‑drug pipeline.
The approvals may lead to dilution and share structure changes, creating short‑term pressure on the stock.
Near-term trading focus is merger execution risk plus cash runway, with additional read-through from Q2 cost and liquidity disclosures.
AlphAI scores every news story that mentions PULM with an AI model for sentiment and relevance, and aggregates insider trades from Pulmatrix, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pulmatrix reported a GAAP EPS of -$0.34 for Q3 2026. The company released this financial update in a press statement.
Pulmatrix (PULM) reported Q3 2026 results, highlighting progress on its merger with Eos SENOLYTIX, expected to close by year-end. The company raised $1M in a private placement related to the merger. Pulmatrix also updated investors on its clinical assets, including PUR1900, PUR3100, and PUR1800, and reported increased expenses due to merger activities. As of Q3 2026, Pulmatrix had $1.4M in cash and cash equivalents.
Eos SENOLYTIX reported interim data from a rat study of its aging drug candidate PTC-2105, showing improved motor performance and reduced fat mass. The 32-week study involves 268 rats, with the oldest cohort showing positive results. Eos plans FDA submission and human trials in 2027. The company is merging with Pulmatrix Inc. (PULM), expected to close in Q4 2026.
Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders In connection with the Merger, Pulmatrix held a special meeting in lieu of the annual meeting of Pulmatrix stockholders on October 26, 2026, at 8:30 a.m. Eastern Time (the “Special Meeting”), at which the Pulmatrix sto
Pulmatrix (Nasdaq: PULM) reported 2Q 2026 results and updated investors on its proposed merger with privately held Eos SENOLYTIX. Pulmatrix filed an S-4 and said the deal is expected to close in 3Q 2026. It raised $1.0 million via a private placement. Cash was $2.2 million at June 30, 2026.
Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharm
Pulmatrix, Inc. has announced a definitive merger agreement to acquire Eos SENOLYTIX, Inc. in a $19 million deal. The combined entity will operate as Eos SENOLYTIX, Inc., trading on Nasdaq under "EOSX," and will focus on developing peptide therapies for aging-related diseases, particularly sarcopenia, through Eos’s MitoXcel platform. The transaction, which includes concurrent private financings, is subject to stockholder approval and regulatory requirements and is expected to close in mid-2026.
Pulmatrix ( NASDAQ:PULM ) , a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025.